Dear Healthcare Provider
Earlier this year Bayer HealthCare informed you of a new strategic agreement transferring to Genzyme Corporation the worldwide development and distribution rights held by Bayer for MabCampath®/Campath® (alemtuzumab), and giving Genzyme exclusive worldwide licenses for Fludara® IV and Oral (fludarabine phosphate) for all present and future indications.
This transaction has now legally “closed” and the products have transferred to Genzyme. To ensure a seamless transition, Bayer and Genzyme are working collaboratively during the transfer operations as from 31 May, 2009 in Israel. As a result you have a mix of Bayer and Genzyme contacts for the near term.
